Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial - Poeschel, V; Held, G; Ziepert, M (Lancet, 2019)
et al.